The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

Background: A total of 2%–7% of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK inhibitors have been used for ALK-positive NSCLC treatment, including crizotinib, alectinib, ceritinib, and brigatinib. Although m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Manag Res
Egile Nagusiak: Hou, Helei, Sun, Dantong, Liu, Kewei, Jiang, Man, Liu, Dong, Zhu, Jingjuan, Zhou, Na, Cong, Jing, Zhang, Xiaochun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6511621/
https://ncbi.nlm.nih.gov/pubmed/31190983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S190098
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak